Correlation Between Esperion Therapeutics and Indaptus Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Indaptus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Indaptus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Esperion Therapeutics and Indaptus Therapeutics, you can compare the effects of market volatilities on Esperion Therapeutics and Indaptus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Indaptus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Indaptus Therapeutics.

Diversification Opportunities for Esperion Therapeutics and Indaptus Therapeutics

-0.48
  Correlation Coefficient

Very good diversification

The 3 months correlation between Esperion and Indaptus is -0.48. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Indaptus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Indaptus Therapeutics and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Indaptus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Indaptus Therapeutics has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Indaptus Therapeutics go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Indaptus Therapeutics

Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 0.61 times more return on investment than Indaptus Therapeutics. However, Esperion Therapeutics is 1.63 times less risky than Indaptus Therapeutics. It trades about 0.14 of its potential returns per unit of risk. Indaptus Therapeutics is currently generating about -0.05 per unit of risk. If you would invest  183.00  in Esperion Therapeutics on August 31, 2024 and sell it today you would earn a total of  71.00  from holding Esperion Therapeutics or generate 38.8% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Esperion Therapeutics  vs.  Indaptus Therapeutics

 Performance 
       Timeline  
Esperion Therapeutics 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Esperion Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively unsteady basic indicators, Esperion Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.
Indaptus Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Esperion Therapeutics and Indaptus Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Esperion Therapeutics and Indaptus Therapeutics

The main advantage of trading using opposite Esperion Therapeutics and Indaptus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Indaptus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will offset losses from the drop in Indaptus Therapeutics' long position.
The idea behind Esperion Therapeutics and Indaptus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance